Tenosynovial Giant Cell Tumor
Conditions
Interventions
Experimental group:The patient received intravenous ICG before conventional resection of tenosynovial giant cell tumor. After the main lesions were removed routinely during the operation, the steps of
Sponsors
Shanghai JiaoTong university Affiliated Sixth People‘s Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Ages 18-75 years;2. TGCT was diagnosed by preoperative needle biopsy or typical imaging (MRI), and surgical resection was planned; 3. Able to understand and voluntarily sign written informed consent.
Exclusion criteria
Exclusion criteria: 1. Have a known history of severe allergy to ICG or iodine; 2. Severe liver dysfunction; 3. Pregnant or lactating women; 4. The lesion site has previously received any form of surgery, radiotherapy or targeted drug therapy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The accuracy of ICG fluorescence imaging in displaying TGCT lesions, including sensitivity, specificity, positive predictive value and negative predictive value; | — |
Secondary
| Measure | Time frame |
|---|---|
| Diagnostic accuracy in the Diffuse-type Tenosynovial Giant Cell Tumor and Localized-type Tenosynovial Giant Cell Tumor subgroups ((Sensitivity, Specificity, Positive Predictive Value, Negative Predictive Value));Tumor-to-Background Ratio, TBR;Spatial overlap of ICG fluorescence boundary and pathological boundary;Correlation between Microvessel Density (MVD) and TBR;Incidence of Adverse Events; | — |
Countries
China
Contacts
Public ContactYang Qingcheng
Shanghai JiaoTong university Affiliated Sixth People‘s Hospital
Outcome results
None listed